Daclatasvir dihydrochloride

Daclatasvir dihydrochloride - the dihydrochloride salt form of daclatasvir, an orally available inhibitor of the hepatitis c virus (hcv) non-structural protein 5a (ns5a) replication complex, with potential activity against hcv. Although the exact mechanism of action of daclatasvir has yet to be fully determined, this agent, upon oral administration and after intracellular uptake, appears to bind to domain I of the ns5a protein. This inhibits the activity of the ns5a protein and results in the disruption of the viral rna replication complex, blockage of viral hcv rna production, and inhibition of viral replication. Ns5a, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in hcv rna replication. Hcv is a small, enveloped, single-stranded rna virus belonging to the flaviviridae family.

Resources

Latest articles - Daclatasvir dihydrochloride

• Most recent articles
• Ongoing trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Daclatasvir dihydrochloride for any updates.

‎